BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.87 USD | +1.12% |
|
+6.04% | -13.02% |
| Jun. 10 | Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion | DJ |
| Jun. 10 | KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 | MT |
Financials (USD)
| Sales 2024 * | 2.74B | Sales 2025 * | 3.08B | Capitalization | 15.93B |
|---|---|---|---|---|---|
| Net income 2024 * | 365M | Net income 2025 * | 501M | EV / Sales 2024 * | 5.56 x |
| Net cash position 2024 * | 698M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 4.73 x |
| P/E ratio 2024 * |
45.5
x | P/E ratio 2025 * |
32.4
x | Employees | 3,401 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.13% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioMarin Pharmaceutical Inc.
More recommendations
More press releases
More news
| 1 day | +1.12% | ||
| 1 week | +6.04% | ||
| Current month | +11.72% | ||
| 1 month | +3.50% | ||
| 3 months | -2.48% | ||
| 6 months | -10.30% | ||
| Current year | -13.02% |
1 week
78.95
85.51
1 month
73.6885.51
Current year
73.6899.25
1 year
73.6899.56
3 years
70.73117.77
5 years
62.88131.95
10 years
55.36151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
C. Guyer
CTO | Chief Tech/Sci/R&D Officer | 62 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Elaine Heron
BRD | Director/Board Member | 76 | 02-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | +0.84% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-11 | 83.87 | +1.12% | 3,214,873 |
| 24-06-10 | 82.94 | +2.79% | 7,450,421 |
| 24-06-07 | 80.69 | -0.20% | 1,495,792 |
| 24-06-06 | 80.85 | +1.48% | 1,966,142 |
| 24-06-05 | 79.67 | +0.73% | 1,949,796 |
Delayed Quote Nasdaq, June 11, 2024 at 04:00 pm EDT
More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
83.87
USD
Average target price
108.1
USD
Spread / Average Target
+28.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.02% | 15.93B | |
| -1.62% | 91.26B | |
| -2.63% | 38.17B | |
| -12.76% | 32.85B | |
| +66.54% | 26.74B | |
| -5.27% | 13.37B | |
| -10.50% | 11.77B | |
| -49.11% | 10.27B | |
| +187.82% | 10.92B | |
| +0.67% | 8.69B |
- Stock Market
- Equities
- BMRN Stock
